51 related articles for article (PubMed ID: 34878824)
21. Targeting lysine-specific demethylase 1 (KDM1A/LSD1) impairs colorectal cancer tumorigenesis by affecting cancer cells stemness, motility, and differentiation.
Antona A; Leo G; Favero F; Varalda M; Venetucci J; Faletti S; Todaro M; Mazzucco E; Soligo E; Saglietti C; Stassi G; Manfredi M; Pelicci G; Corà D; Valente G; Capello D
Cell Death Discov; 2023 Jun; 9(1):201. PubMed ID: 37385999
[TBL] [Abstract][Full Text] [Related]
22. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
23. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles.
Stitzlein LM; Gangadharan A; Walsh LM; Nam D; Espejo AB; Singh MM; Patel KH; Lu Y; Su X; Ezhilarasan R; Gumin J; Singh S; Sulman E; Lang FF; Chandra J
Front Neurol; 2023; 14():1112207. PubMed ID: 37082446
[TBL] [Abstract][Full Text] [Related]
24. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
[TBL] [Abstract][Full Text] [Related]
25. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma.
Ferrarese R; Izzo A; Andrieux G; Lagies S; Bartmuss JP; Masilamani AP; Wasilenko A; Osti D; Faletti S; Schulzki R; Yuan S; Kling E; Ribecco V; Heiland DH; Tholen S; Prinz M; Pelicci G; Kammerer B; Boerries M; Carro MS
Life Sci Alliance; 2023 Jan; 6(1):. PubMed ID: 36414381
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
27. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.
Luo W; Li X; Song Z; Zhu X; Zhao S
Aging (Albany NY); 2019 Jun; 11(11):3811-3823. PubMed ID: 31186379
[TBL] [Abstract][Full Text] [Related]
29. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
Barone A; Sengupta R; Warrington NM; Smith E; Wen PY; Brekken RA; Romagnoli B; Douglas G; Chevalier E; Bauer MP; Dembowsky K; Piwnica-Worms D; Rubin JB
Oncotarget; 2014 Oct; 5(20):9811-22. PubMed ID: 25238146
[TBL] [Abstract][Full Text] [Related]
30. LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response.
Faletti S; Osti D; Ceccacci E; Richichi C; Costanza B; Nicosia L; Noberini R; Marotta G; Furia L; Faretta MR; Brambillasca S; Quarto M; Bertero L; Boldorini R; Pollo B; Gandini S; Cora D; Minucci S; Mercurio C; Varasi M; Bonaldi T; Pelicci G
Sci Transl Med; 2021 Dec; 13(623):eabf7036. PubMed ID: 34878824
[TBL] [Abstract][Full Text] [Related]
31. Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy.
Mitra R; Ayyannan SR
Anticancer Agents Med Chem; 2022; 22(18):3062-3085. PubMed ID: 35593350
[TBL] [Abstract][Full Text] [Related]
32. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
Nana AW; Yang PM; Lin HY
Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
